Monkeys |
Severe acute respiratory syndrome |
SARS-CoV S |
Beaudette C |
SARS-CoV S-specific CD8+ T cells |
[49] |
Camel |
Middle east respiratory syndrome |
MERS-CoV S |
LaSota |
Neutralizing antibodies |
[50] |
Cattle |
Rift valley fever |
RVFV Gn |
LaSota |
Neutralizing antibodies |
[51] |
Cattle |
Infectious bovine rhinotracheitis |
BHV-1 gD |
LaSota |
Neutralizing IgG and IgA |
[52] |
Cattle |
Bovine ephemeral fever |
BEFV G |
Lasota |
Neutralizing antibodies |
[53] |
Chicken |
Infectious bronchitis |
IBV S1 or full S |
Lasota |
CD4+ and CD8+ cells; Neutralizing antibodies |
[42,54] |
Chicken |
Infectious laryngotracheitis |
ILTV gD |
Lasota |
Neutralizing antibodies |
[55] |
Chicken |
Highly pathogenic avian influenza |
H5, H7, H9 |
Lasota |
Neutralizing antibodies |
[56,57] |
Chicken |
Infectious bursal disease |
IBDV VP2 |
Lasota |
- |
[58] |
Dogs and cats |
Rabies |
RV G |
Lasota |
Neutralizing antibodies |
[59] |
Goose |
Gosling plaque |
VP3 of goose parvovirus |
NA-1 |
Neutralizing antibodies |
[60] |
Guinea pigs |
Acquired immune deficiency syndrome |
HIV gp160 |
Lasota |
Neutralizing antibodies |
[61] |
Horse |
West Nile fever |
WNV PrM/E
|
Lasota |
CD4+ and CD8+ cells; Neutralizing IgG |
[62] |
Mice |
Acute pneumonia |
RSV F |
Hitchner B1 |
CD8+ cells |
[63] |
Mice |
Nipah encephalitis |
Nipah virus G and F |
Lasota |
T and B cells; Neutralizing antibodies |
[64] |
Mice |
Vesicular stomatitis |
VSV G |
LaSota |
Neutralizing antibodies |
[65] |
Mice |
Viral gastroenteritis |
NV VP1 |
LaSota and Beaudette C |
CD8+ cells; Neutralizing antibodies |
[66] |
Minks |
Canine distemper |
CDV F and HN |
LaSota |
Neutralizing antibodies |
[67] |
Monkey |
Ebola |
EBOV GP |
Beaudette C |
CD8+ cells: virus specific IgA, and IgG |
[68,69] |
Pigs |
Nipah encephalitis |
Nipah virus G and F |
LaSota |
T and B cells; Neutralizing antibodies |
[64] |
Monkeys |
Parainfluenza |
HPIV3 HN |
Beaudette C |
Neutralizing antibodies |
[70] |
Turkey |
Turkeys rhinotracheitis |
F and G of AMPV type CG of AMPV type A and B |
LaSota |
Neutralizing antibodies |
[48,71] |